[New Albany, Ohio, February 1, 2024] — AmplifyBio, a leading commercialization partner for advanced therapies that include cell and gene therapies, proudly announces the successful grand opening of the AmplifyBio Manufacturing Enablement Center (AMEC) in New Albany, Ohio. The milestone event follows the addition of a site dedicated to drug discovery, optimization and characterization work acquired last year in South San Francisco and the original spin out of a preclinical CRO business from Battelle in May of 2021.
The opening event was attended by AmplifyBio executive leadership, staff, esteemed board members, including Battelle CEO Lou Von Thaer, and distinguished guests from the wider Central Ohio life sciences community and marked a significant achievement in the company’s evolution.
Held at the state-of-the-art facility in New Albany, the guests also included leaders from Ohio Life Sciences, city officials from New Albany, investors, members of the press, and colleagues from neighboring life science organizations. The gathering commenced with a reception, fostering networking opportunities and collaboration among attendees.
Guests were treated to informative tours of the AMEC facility, showcasing grade B and grade C manufacturing suites available for lease to clients. AmplifyBio’s varied operating models that include full outsourcing, a full “hoteling” model, and a hybrid collaborative model were highlighted during the tours, showcasing the company’s commitment to providing flexible and innovative manufacturing and technology solutions.
Remarks from Key Speakers:
Jae Yoon, CFO and Executive VP of Strategy for AmplifyBio, expressed gratitude to supportive investors, community members, and dedicated staff for the achievement. Eddie Pauline, CEO of Ohio Life Sciences, spoke enthusiastically about AmplifyBio’s contribution to the growing life science ecosystem in Central Ohio. He emphasized the importance of collaboration in fostering a conducive environment for biotech growth in the region.
The program culminated with remarks from AmplifyBio CEO, J. Kelly Ganjei, and AmplifyBio Board Chairman and Battelle CEO, Lou Von Thaer. Both leaders highlighted the significant milestone and reiterated the company’s commitment to being a service provider that is committed to offering comprehensive solutions to critical challenges facing advanced therapy developers.
“It’s a very exciting day for AmplifyBio,” said J. Kelly Ganei, CEO, “The opening of AMEC is just one more step in our journey to be a partner with the experience and technological environment that can significantly reduce the time and safety risks for developers bringing these life changing drugs to the patients who are anxiously waiting for them.”
The event concluded with a symbolic ribbon-cutting ceremony, signifying the official opening of the AMEC facility. Opening the manufacturing facility is an important component in AmplifyBio’s vision to provide capable capacity for the development and manufacturing of advanced modality drugs. The company’s three sites seamlessly integrate expertise and technology in a flexible environment where developers can ensure the right parameters for safety and reproducibility are maintained from concept to commercial.